GANAB and N-Glycans Substrates Are Relevant in Human Physiology, Polycystic Pathology and Multiple Sclerosis: A Review
Open accessThe DOI matches its Crossref record; 454 of the 464 references it cites were found in a registry or an index; 60 of the 171 sources its claims cite were checked for support.
Abstract
Glycans are one of the four fundamental macromolecular components of living matter, and they are highly regulated in the cell. Their functions are metabolic, structural and modulatory. In particular, ER resident N-glycans participate with the Glc3Man9GlcNAc2 highly conserved sequence, in protein folding process, where the physiological balance between glycosylation/deglycosylation on the innermost glucose residue takes place, according GANAB/UGGT concentration ratio. However, under abnormal conditions, the cell adapts to the glucose availability by adopting an aerobic or anaerobic regimen of glycolysis, or to external stimuli through internal or external recognition patterns, so it responds to pathogenic noxa with unfolded protein response (UPR). UPR can affect Multiple Sclerosis (MS) and several neurological and metabolic diseases via the BiP stress sensor, resulting in ATF6, PERK and IRE1 activation. Furthermore, the abnormal GANAB expression has been observed in MS, systemic lupus erythematous, male germinal epithelium and predisposed highly replicating cells of the kidney tubules and bile ducts. The latter is the case of Polycystic Liver Disease (PCLD) and Polycystic Kidney Disease (PCKD), where genetically induced GANAB loss affects polycystin-1 (PC1) and polycystin-2 (PC2), resulting in altered protein quality control and cyst formation phenomenon. Our topics resume the role of glycans in cell physiology, highlighting the N-glycans one, as a substrate of GANAB, which is an emerging key molecule in MS and other human pathologies.
Overview
CoChat Summary
TL;DR
This review synthesizes glycobiology and the roles of GANAB/glucosidase II in ER N-glycan processing, unfolded protein response, and human disease. It highlights GANAB dysregulation in multiple sclerosis, polycystic liver/kidney disease, systemic lupus erythematosus, and other conditions, proposing GANAB as a biomarker and therapeutic target.
Key findings
- GANAB encodes the catalytic α-subunit of glucosidase II (GII), a heterodimer with the β-subunit PRKCSH; the human α-subunit is 944 amino acids with a 912-amino-acid catalytic domain (~103 kDa), and the β-subunit is 528 amino acids (~58 kDa). GII trims glucose residues from the Glc3Man9GlcNAc2 N-glycan in ER glycoprotein quality control.
- GANAB expression is highest in liver, followed by epididymis ductal cells, with kidney among top expression sites; abnormal GANAB expression is reported in multiple sclerosis (MS), systemic lupus erythematosus, male germinal epithelium, and highly replicating kidney tubule/bile duct cells.
- In MS, GANAB was upregulated in untreated relapsing-remitting MS patients compared with IFN-treated and other disease-modifying-therapy-treated patients, downregulated in treatment responders versus nonresponders, and higher in healthy controls than untreated RRMS patients; it correlated with lesion load, disease duration, and the Rio score.
- In autosomal dominant polycystic liver and kidney disease, GANAB mutations cause defective glucose trimming of N-glycan moieties and increased apparent molecular mass of polycystin-1; ADPLD genes explain only 25–30% of the genetic spectrum, and GANAB loss affects polycystin-1/polycystin-2 and cyst formation.
Methods
- Narrative review of glycobiology, GANAB/glucosidase II structure and function, unfolded protein response, and disease literature; no systematic review protocol or meta-analysis is described.
- Evidence is drawn from cited experimental, genetic, clinical, and animal studies; no primary data collection or new patient cohort is reported.
- Main analysis is a qualitative synthesis linking GANAB/N-glycan biology to human physiology and pathologies.
Limitations
- The authors state that glycomics knowledge is scattered and lacks a holistic/systematic view; for MS, no other published articles on GANAB were available to them; except for MS and polycystic kidney/liver disease, the relation between human pathology and α-glycosidases is only conceivable and not concretely demonstrated; more comprehensive studies are warranted.
- Evident from the text: as a narrative review, it lacks systematic search/selection criteria and formal quality assessment, so selection bias and reliance on heterogeneous evidence are possible.
- Evident from the text: conclusions often rest on animal or cell models and correlative human findings, so causality is not established.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
54 Valid · 22 Not valid · 70 Not checked · 43 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In addition, Glucosidase II is involved in human polycystic disease [8,9,10] and finally in the demyelinating ones of the central nervous system (CNS), according to the latest evidence [11].”
§ GANAB and N-Glycans Substrates Are Relevant in Human Physiology, Polycystic Pathology and Multiple Sclerosis: A Review > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [8] Drenth J.P. te Morsche R.H. Smink R. Bonifacino J.S. Jansen J.B. Germline mutations in PRKCSH are associated with autosomal dominant polycystic liver disease Nat. Genet. 2003 33 345 347 10.1038/ng1104 12577059 source
- Not checked — no full text of the sourcecites [9] Li A. Davila S. Furu L. Qian Q. Tian X. Kamath P.S. King B.F. Torres V.E. Somlo S. Mutations in PRKCSH cause isolated autosomal dominant polycystic liver disease Am. J. Hum. Genet. 2003 72 691 703 10.1086/368295 12529853 PMC1180260 source
- Supportedcites [10] Porath B. Gainullin V.G. Cornec-Le Gall E. Dillinger E.K. Heyer C.M. Hopp K. Edwards M.E. Madsen C.D. Mauritz S.R. Banks C.J. Genkyst Study Group; HALT Progression of Polycystic Kidney Disease Group; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease; Harris, P.C. Mutations in GANAB, Encoding the Glucosidase IIα Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease Am. J. Hum. Genet. 2016 98 1193 1207 10.1016/j.ajhg.2016.05.004 27259053 PMC4908191 source
The Results identify GANAB as encoding the catalytic α subunit of glucosidase II and link mutations in the enzyme’s β subunit to polycystic liver disease. The paper’s title and figure legend also link GANAB mutations to affected people with kidney and liver cysts, supporting the broad claim that glucosidase II is involved in human polycystic disease. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“We know why partially glycosylated proteins have a shorter lifetime than fully glycosylated ones, due to the binding of galactose with hepatic asialoglycoprotein receptors expressed on hepatocytes, which promotes hepatic clearance of the partially glycosylated proteins [217].”
§ GANAB and N-Glycans Substrates Are Relevant in Human Physiology, Polycystic Pathology and Multiple Sclerosis: A Review > 6. Glycodrugs
What the sources say
- Supportedcites [217] Zhang L. Luo S. Zhang B. Glycan analysis of therapeutic glycoproteins MAbs 2016 8 205 215 10.1080/19420862.2015.1117719 26599345 PMC4966609 source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Many studies have found evidence of sustained and high-level activation of all three branches of the UPR (PERK, ATF6, IRE1α) in different tumors, including glioblastoma, MM, carcinomas of the breasts, stomach, esophagus, and liver [304,406,407,408,409].”
§ GANAB and N-Glycans Substrates Are Relevant in Human Physiology, Polycystic Pathology and Multiple Sclerosis: A Review > 9. UPR in Human Diseases: The Role of GII > 9.3. Cancer
What the sources say
- Not checked — no full text of the sourcecites [304] Shuda M. Kondoh N. Imazeki N. Tanaka K. Okada T. Mori K. Hada A. Arai M. Wakatsuki T. Matsubara O. Activation of the atf6, xbp1 and grp78 genes in human hepatocellular carcinoma: A possible involvement of the er stress pathway in hepatocarcinogenesis J. Hepatol. 2003 38 605 614 10.1016/S0168-8278(03)00029-1 12713871 source
- Partly supportedcites [406] Carrasco D.R. Sukhdeo K. Protopopova M. Sinha R. Enos M. Carrasco D.E. Zheng M. Mani M. Henderson J. Pinkus G.S. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis Cancer Cell 2007 11 349 360 10.1016/j.ccr.2007.02.015 17418411 PMC1885943 sourceExperimental — accuracy not yet measured
The Introduction reports elevated XBP-1 expression in multiple myeloma, breast tumors, and hepatocellular carcinomas, while the Discussion links sustained XBP-1s overexpression to myeloma development. The paper does not establish sustained, high-level activation of all three UPR branches in those tumors, or address that claim for glioblastoma, stomach, or esophageal carcinomas. Page numbers were not available in our copy. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [407] Fernandez P.M. Tabbara S.O. Jacobs L.K. Manning F.C. Tsangaris T.N. Schwartz A.M. Kennedy K.A. Patierno S.R. Overexpression of the glucose-regulated stress gene GRP78 in malignant but not benign human breast lesions Breast Cancer Res. Treat. 2000 59 15 26 10.1023/A:1006332011207 10752676 source
- Not checked — no full text of the sourcecites [408] Song M.S. Park Y.K. Lee J.H. Park K. Induction of glucose-regulated protein 78 by chronic hypoxia in human gastric tumor cells through a protein kinase C-ε/ERK/AP-1 signaling cascade Cancer Res. 2001 61 8322 8330 11719466
- Not checked — no full text of the sourcecites [409] Chen X. Ding Y. Liu C.G. Mikhail S. Yang C.S. Overexpression of glucose-regulated protein 94 (Grp94) in esophageal adenocarcinomas of a rat surgical model and humans Carcinogenesis 2002 23 123 130 10.1093/carcin/23.1.123 11756233 source
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Studies revealed that mutations in Prksch or Sec63 greatly reduce the expression, stability and proper trafficking of polycystin-1 (PC1), leading to cyst formation in a dose-dependent manner [426,427].”
§ GANAB and N-Glycans Substrates Are Relevant in Human Physiology, Polycystic Pathology and Multiple Sclerosis: A Review > 9. UPR in Human Diseases: The Role of GII > 9.5. ADPLD and ADPKD
What the sources say
- Not checked — no full text of the sourcecites [426] Waanders E. te Morsche R.H. de Man R.A. Jansen J.B. Drenth J.P. Extensive mutational analysis of PRKCSH and SEC63 broadens the spectrum of polycystic liver disease Hum. Mutat. 2006 27 830 10.1002/humu.9441 16835903 source
- Partly supportedcites [427] Hopp K. Ward C.J. Hommerding C.J. Nasr S.H. Tuan H.F. Gainullin V.G. Rossetti S. Torres V.E. Harris P.C. Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity J. Clin. Investig. 2012 122 4257 4273 10.1172/JCI64313 23064367 PMC3484456 sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) links lower mature PC-1 dosage to more severe cystic disease, supporting the dose-dependent part of the claim. But the paper studies a Pkd1 variant, not mutations in Prksch or Sec63; its Figure 8 passage says the mutant PC-1 that reached urinary vesicles trafficked appropriately. It therefore does not establish the claimed effects of those two genes on PC-1 expression, stability, or trafficking. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“The level of functional PC1 at the cilium is thought to be central to the development of both hepatic and kidney cysts [428].”
§ GANAB and N-Glycans Substrates Are Relevant in Human Physiology, Polycystic Pathology and Multiple Sclerosis: A Review > 9. UPR in Human Diseases: The Role of GII > 9.5. ADPLD and ADPKD
What the sources say
- Supportedcites [428] Kim H. Xu H. Yao Q. Li W. Huang Q. Outeda P. Cebotaru V. Chiaravalli M. Boletta A. Piontek K. Ciliary membrane proteins traffic through the Golgi via a Rabep1/GGA1/Arl3-dependent mechanism Nat. Commun. 2014 5 5482 10.1038/ncomms6482 25405894 PMC4237283 source
The Discussion calls PC1 the central determinant of cyst formation in polycystic kidney and liver diseases and identifies it as the rate-limiting factor for ciliary trafficking of the polycystin complex. The paper also states that loss of polycystin function in cilia is implicated in cyst formation. Together, these support the citing sentence’s hedged claim. (LLM, conf=0.87)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
85 more claims · 26 with their cited sources checked
Create a free account to see all 189 claims and to verify the 17 references still open.
- It may state two separate claims as one. 56
- Probably not a substantial claim. 68
- The quote only partly states this claim. 1
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ GANAB and N-Glycans Substrates Are Relevant in Human Physiology, Polycystic Pathology and Multiple Sclerosis: A Review > 7. Protein Folding and Folding Quality Control Machinery > The UPR
“the α-GluI operates a first cleavage by removing a glucose residue from the conserved Glc2Man9GlcNAc2 N-linked glycan attached to nascent glycoprotein, and the resulting Glc1Man9GlcNAc2 glycan”
§ GANAB and N-Glycans Substrates Are Relevant in Human Physiology, Polycystic Pathology and Multiple Sclerosis: A Review > 7. Protein Folding and Folding Quality Control Machinery > The UPR
“ER-resident GluI and GluII sequentially trim the three terminal glucose moieties on N-linked Glc3Man9GlcNAc2 glycan coupled en bloc to nascent glycoproteins by oligosaccharyltransferase (OST)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ GANAB and N-Glycans Substrates Are Relevant in Human Physiology, Polycystic Pathology and Multiple Sclerosis: A Review > 10. Conclusions
“the catalytic one is responsible for innermost glucose trimming on the Glc3Man9GlcNAc2 precursor signal. This reaction allows the nascent peptide to enter the CNX/CRT cycle for maturation.”
§ GANAB and N-Glycans Substrates Are Relevant in Human Physiology, Polycystic Pathology and Multiple Sclerosis: A Review > 9. UPR in Human Diseases: The Role of GII > 9.5. ADPLD and ADPKD
“The subsequent removal of the innermost glucose by GII allows for the exit of the protein, if properly folded. In this case, it can proceed along the secretory pathway.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ GANAB and N-Glycans Substrates Are Relevant in Human Physiology, Polycystic Pathology and Multiple Sclerosis: A Review > 6. Glycodrugs > 6.3. Viral Infections and Glycodrugs
“The FDA-approved drug is called Relenza.”
§ GANAB and N-Glycans Substrates Are Relevant in Human Physiology, Polycystic Pathology and Multiple Sclerosis: A Review > 4. Recognition Patterns of Glycans
“the specific neuraminidase inhibitor zanamivir (Relenza) [103,104] projected onto the previously known sialidase inhibitor Neu5Ac2en [105]”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ GANAB and N-Glycans Substrates Are Relevant in Human Physiology, Polycystic Pathology and Multiple Sclerosis: A Review > 8. The GANAB > 8.1. The Structure and Localization Glucosidase II
“the inner one exposes the Glc residue to the catalytic site on the GIIβ [369].”
§ GANAB and N-Glycans Substrates Are Relevant in Human Physiology, Polycystic Pathology and Multiple Sclerosis: A Review > 8. The GANAB > 8.1. The Structure and Localization Glucosidase II
“α-Glucosidase II (GluII or GII) consists of a 110 kDA catalytic α-subunit (GIIα) and 60 kDA regulatory β-subunit (GIIβ).”
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“stress resulting in the induction of UPR, chaperones, and apoptotic markers [400,401].”
Cited work 10.1016/j.nbd.2008.02.009 · retracted 2020-12-25 · notice 10.1016/j.nbd.2020.105232 · this paper published 2022-07-01
Citations
Cites
1 retracted
Items 401–454 of 454
Glucosidase II from rat liver microsomes. Kinetic model for binding and hydrolysis
Alonso, J. M., SANTA-CECILIA, A., & Calvo, P. (1991) · Biochemical Journal · doi:10.1042/bj2780721 · Cited by 31 · cited 1×
“A unit of enzyme activity is defined as the amount of enzyme that releases 1 mmol of p-nitrophenol/min [375].”
BackgroundCommentary: C‐type lectins on the macrophage cell surface – recent findings
Marshall, A. S. J., & Gordon, S. (2003) · European Journal of Immunology · doi:10.1002/eji.200324641 · Cited by 31 · cited 1×
“In immunological terms, it is also known that immune cells can elicit the innate immune response by detecting damage-associated molecular patterns (DAMPs) or pathogenassociated molecular patterns (PAMPs) using Pattern Recognition Receptors (PRRs) [107], such as Toll-like receptors (TLRs) [108,109], NOD-like receptors…”
BackgroundIntroduction to glycopathology: The concept, the tools and the perspectives
Gabius, H.-J., & Kayser, K. (2014) · Diagnostic Pathology · doi:10.1186/1746-1596-9-4 · Cited by 31
Role of ligands of receptor for advanced glycation end products (RAGE) in peripheral artery disease
Yamagishi, S.-I., & Matsui, T. (2018) · Rejuvenation Research · doi:10.1089/rej.2017.2025 · Cited by 31 · cited 1×
“Thus, accumulated AGEs in the skin can currently be estimated using the non-invasive autofluorescence measurement [206].”
BackgroundAffinity purification and characterization of glucosidase II from pig liver
Hentges, A., & Bause, E. (1997) · Biological Chemistry · doi:10.1515/bchm.1997.378.9.1031 · Cited by 29 · cited 1×
“Regarding interactions, unlike the UGGT that does not have an identified inhibitor (apart from its product, UDP) [319], GII inhibitors include the pyranose sugar analogues 1-deoxynojirimycin, N-5-carboxypentyl-dNM, and castanospermine, all iminosugars [218,376,377].”
BackgroundTempio, T., Orsi, A., Sicari, D., Valetti, C., Yoboue, E. D., Anelli, T., & Sitia, R. (2021) · iScience · doi:10.1016/j.isci.2021.102244 · Cited by 29 · cited 1×
“Other protein is ERp44, which is located in the ER–Golgi intermediate compartment (ERGIC), and engaged in the folding/oligomerization or retention of some proteins [352].”
BackgroundComputational aspects in mechanical modeling of the articular cartilage tissue
Mohammadi, H., Mequanint, K., & Herzog, W. (2013) · Proceedings of the Institution of Mechanical Engineers, Part H: Journal of Engineering in Medicine · doi:10.1177/0954411912470239 · Cited by 28
Gu, J.-L., Li, J., Zhou, Z.-H., Liu, J.-R., Huang, B.-H., Zheng, D., & Su, C. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.03.056 · Cited by 28 · cited 2×
“Anyway, in this topic, we have of a proteasome inhibitor, Bortezomib.”
BackgroundExpression of genes that control core fucosylation in hepatocellular carcinoma: Systematic review
Norton, P. A., & Mehta, A. S. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i23.2947 · Cited by 28 · cited 1×
“Finally, an altered expression of genes controlling core fucosylation has been recognized as responsible for hepatocellular carcinoma [144].”
BackgroundLi, Q., & Ye, X. (2015) · Israel Journal of Chemistry · doi:10.1002/ijch.201400150 · Cited by 28
Curia, G., Aracri, P., Colombo, E., et al. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707144 · Cited by 28 · cited 1×
“Topiramate, a sulfamate-substituted monosaccharide, has been approved by the FDA for the treatment of epilepsy, Lennox–Gastaut syndrome, and for the prevention of migraines [278].”
BackgroundImmunosenescence: the role of age in multiple sclerosis
Ibáñez, A. O., Laviñeta, J. C., & Blanco, T. A. (2022) · Neurología (English Edition) · doi:10.1016/j.nrleng.2020.05.023 · Cited by 28
New discriminatory level for glucosidase activity to diagnose epididymal obstruction or dysfunction
Kret, B., Milad, M., & Jeyendran, R. S. (1995) · Archives of Andrology · doi:10.3109/01485019508987850 · Cited by 27
Latov, N. (2021) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000975 · Cited by 27 · cited 1×
“Known glycan self-antigens are MOG for MS, Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and NMO/NMOSD [123–125]; MAG for human demyelinating neuropathy [126]; GM1, GD1a, GT1a and GQ1b for GBS [127]; the latter also for BBE [128]; and N-acetylglucosamine-6-sulfatase (GNS) for Rheumatoid Arthr…”
BackgroundDe Masi, R., Vergara, D., Pasca, S., Acierno, R., Greco, M., Spagnolo, L., Blasi, E., Sanapo, F., Trianni, G., & Maffia, M. (2009) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2009.03.002 · Cited by 26 · cited 1×
“In 2009, De Masi and coworkers first evidenced GANAB as a differentially expressed protein from PBMCs in naive patients compared to the RRMS ones undergoing IFN therapy [447].”
ResultInhibition of experimental allergic encephalomyelitis by the α-glucosidase inhibitor castanospermine
Willenborg, D. O., Parish, C. R., & Cowden, W. B. (1989) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(89)90047-6 · Cited by 26
Chemistry and Function of Glycosaminoglycans in the Nervous System
Schwartz, N. B., & Domowicz, M. S. (2014) · Advances in Neurobiology · doi:10.1007/978-1-4939-1154-7_5 · Cited by 25
N-Glycan processing and glycoprotein folding
Trombetta, E. S., & Parodi, A. J. (2001) · Advances in protein chemistry · doi:10.1016/s0065-3233(01)59010-5 · Cited by 25
C-Mannosylation: Modification on Tryptophan in Cellular Proteins
Ihara, Y., Inai, Y., Ikezaki, M., Matsui, I.-S. L., Manabe, S., & Ito, Y. (2014) · Springer eBooks · doi:10.1007/978-4-431-54841-6_67 · Cited by 25
A Model of the Unfolded Protein Response: Pancreatic β-Cell as a Case Study
Schnell, S. D. (2009) · Cellular Physiology and Biochemistry · doi:10.1159/000218170 · Cited by 25
Meurs, A., Clinckers, R., Ebinger, G., Michotte, Y. M., & Smolders, I. J. (2006) · Epilepsia · doi:10.1111/j.1528-1167.2006.00625.x · Cited by 25
Lactulose--a multifaceted substance.
Huchzermeyer, H., & Schumann, C. (1997) · PubMed · Cited by 25
Inmunosenescencia: el rol de la edad en la esclerosis múltiple
Ostolaza, A., Laviñeta, J. C., & Blanco, T. A. (2020) · Neurología · doi:10.1016/j.nrl.2020.05.016 · Cited by 25 · cited 1×
“HCs and RRMS has been attributed to the well-known phenomenon of immunosenescence already described in MS [449,450].”
BackgroundUtility of the Rio Score and Modified Rio Score in Korean Patients with Multiple Sclerosis
Hyun, J., Kim, S., Jeong, I. H., Ahn, S.-W., Huh, S., Park, M. S., Eom, Y. I., Joo, I. S., Cho, J., Cho, E. B., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0129243 · Cited by 24 · cited 1×
“The Rio score is a gold-standard method to classify the risk of disease progression based on one-year clinical/paraclinical observations in IFN-treated MS patients [448].”
MethodOlson, L. J., Orsi, R., Alculumbre, S. G., Peterson, F. C., Stigliano, I. D., Parodi, A. J., D'Alessio, C., & Dahms, N. M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.450239 · Cited by 24
Dhananjayan, K., Gunawardena, D., Hearn, N., Sonntag, T., Moran, C., Gyengesi, E., Srikanth, V., & Münch, G. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161152 · Cited by 24
National Research Council (2012) · National Academies Press eBooks · doi:10.17226/13446 · Cited by 23
Imino sugar glucosidase inhibitors as broadly active anti-filovirus agents
Chang, J., Guo, J.-T., Du, Y., & Block, T. (2013) · Emerging Microbes & Infections · doi:10.1038/emi.2013.77 · Cited by 22 · cited 2×
“Indeed, iminosugars do not need to be glycosidase inhibitors for pharmacological activity, but a lack of glycosidase inhibition removes many off-target activities [223].”
BackgroundNatural Killer Cell Activation Receptor NKp30 Oligomerization Depends on Its N-Glycosylation
Skořepa, O., Pazicky, S., Kalousková, B., Bláha, J., Abreu, C., Ječmen, T., Rosůlek, M., Fish, A., Sedivy, A., Harlos, K., et al. (2020) · Cancers · doi:10.3390/cancers12071998 · Cited by 21 · cited 1×
“This is the case of the CD337 receptor on Natural Killer cells indicating the recognized cell as cancerous [157].”
BackgroundParodi, B., Sanna, A., Cedola, A., Uccelli, A., & Kerlero de Rosbo, N. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.655212 · Cited by 20 · cited 1×
“This small molecule is thought to affect disease progression and neuroinflammation by acting on the Hydroxycarboxylic Acid Receptor 2 (HCAR2) as well [454].”
BackgroundMetabolic transit of dietary advanced glycation end-products—the case of NƐ-carboxymethyllysine
Tessier, F. J., Boulanger, E., & Howsam, M. (2021) · Glycoconjugate Journal · doi:10.1007/s10719-020-09950-y · Cited by 19
Endoplasmic reticulum stress response as a potential therapeutic target in multiple sclerosis
Getts, M. T., Getts, D. R., Kohm, A. P., & Miller, S. D. (2008) · Therapy · doi:10.2217/14750708.5.5.631 · Cited by 18 · cited 1×
“Regarding MS, although ER stress was postulated [336], no specific aggregation or misfolded protein was found, while in main neurodegenerative diseases such as PD, Huntington, AD, familial Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP), emerging evidence indicates pathogenic misfolding pr…”
BackgroundEndoplasmic reticulum stress links psoriasis vulgaris with keratinocyte inflammation
Zhao, M., Luo, J., Xiao, B., Tang, H., Song, F., Ding, X., & Yang, G. (2020) · Advances in Dermatology and Allergology · doi:10.5114/ada.2020.93382 · Cited by 18 · cited 1×
“In addition, this finding is consistent with the alleviation of psoriasis vulgaris, also biologically characterized by UPR [455,456].”
Result1,2,3-Triazoles: Synthesis and Biological Application
Ali, A. A. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.92692 · Cited by 18
The Glycome of Normal and Malignant Plasma Cells
Moehler, T. M., Seckinger, A., Hose, D., Andrulis, M., Moreaux, J., Hielscher, T., Willhauck-Fleckenstein, M., Merling, A., Bertsch, U., Jauch, A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083719 · Cited by 17 · cited 1×
“Among 243 glycogenes, 60 showed a significantly higher expression in MM than normal plasma cell samples, while 20 showed a lower one [141].”
BackgroundFeng, J. (2004) · Glycobiology · doi:10.1093/glycob/cwh110 · Cited by 17 · cited 2×
“The α-subunit contains a GH31 consensus sequence domain (G/F)-(L/I/V/M)-W-X-D-M-N-E providing a nucleophile retaining enzyme mechanism [365,366].”
BackgroundMishra, N., Tiwari, V. K., & Schmidt, R. R. (2020) · Carbohydrates in Drug Discovery and Development · doi:10.1016/b978-0-12-816675-8.00001-4 · Cited by 17 · cited 1×
“This results in an intracellular increase in sodium ions concentration that triggers intracellular Ca+ accumulation facilitating, in turn, the release of calcium ions by sarcoplasmic reticulum, with a final improvement of ionotropism and contractility [266].”
BackgroundFederico, G., Gori, M., Randazzo, E., & Vierucci, F. (2016) · SAGE Open Medicine · doi:10.1177/2050312116682126 · Cited by 16 · cited 1×
“Cooking foods and smoking are associated with exogenous AGEs as well [196,197].”
BackgroundTrends in glycolipid biomarker discovery in neurodegenerative disorders by mass spectrometry
Dehelean, L., Sarbu, M., Petrut, A., & Zamfir, A. D. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-15950-4_42 · Cited by 16 · cited 1×
“Finally, recent mass spectrometry studies recognized glycolipids as potential biomarkers for various physiological and pathological processes, being involved in the development of neurological and neurodegenerative diseases, including Parkinson’s disease (PD), Alzheimer’s disease (AD), Lewy body and frontotemporal dem…”
BackgroundDual topology of co-chaperones at the membrane of the endoplasmic reticulum
Daverkausen-Fischer, L., & Pröls, F. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00594-x · Cited by 16
Large Deletions in GANAB and SEC63 explain 2 cases of polycystic kidney and liver disease
Wilson, E. M., Choi, J., Torres, V. E., Somlo, S., & Besse, W. (2020) · Kidney International Reports · doi:10.1016/j.ekir.2020.01.009 · Cited by 13 · cited 1×
“At present, genes responsible for ADPLD are PRKCSH, SEC63, SEC61B, GANAB, ALG8, DNAJB11 and ALG9, which only explain 25–30% of the genetic spectrum of disease [429,430].”
BackgroundSternberg, Z., Chiotti, A., Tario, J., Chichelli, T., Patel, N., Chadha, K., Yu, J., & Karmon, Y. (2016) · Immunobiology · doi:10.1016/j.imbio.2015.09.007 · Cited by 12 · cited 1×
“In MS, these metabolic modifications refer to T-cells and monocytes, but also to astrocytes after uptake of myelin and oligodendrocytes [212].”
BackgroundPyke, D. A. (1969) · Journal of Clinical Pathology · doi:10.1136/jcp.22.suppl_2.57 · Cited by 12 · cited 1×
“The early phase of this condition is described as physiological for the CNS, being entirely dependent the glycidic metabolism and also able to extract the ATP molecules from ketone bodies; instead, the advanced phase, known as “ketosis”, is characterized by severe acidosis and ultimately by coma [22].”
BackgroundGlycation of extracellular matrix proteins and its role in atherosclerosis
Kuzan, A., Chwiłkowska, A., Kobielarz, M., Pezowicz, C., & Gamian, A. (2012) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.5604/17322693.1016359 · Cited by 11 · cited 1×
“In addition, the aminoguanidine, a Maillard blocker, induces a positive effect in reducing AGE accumulation in tissues in experimental diabetes and preventing the age-related cardiac hypertrophy and arterial stiffening [201].”
BackgroundThe Relevance of Neutral α-Glucosidase Activity in Andrology
Levrant, S., Watanabe, M., Land, S., Sauer, R., & Jeyendran, R. S. (2009) · Systems Biology in Reproductive Medicine · doi:10.1080/19396360902801935 · Cited by 11
Lee, E. S., Kim, J., Lee, H., Ryu, J., Lee, H., Sonn, J. K., & Lim, Y.-B. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00417 · Cited by 11
Use of a Phage Display Antibody to Measure the Enzymatic Activity of the Sulfs
Uchimura, K., Lemjabbar‐Alaoui, H., Kuppevelt, T. H. V., et al. (2010) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(10)80003-5 · Cited by 10
GANAB as a Novel Biomarker in Multiple Sclerosis: Correlation with Neuroinflammation and IFI35
De Masi, R., & Orlando, S. (2021) · Pharmaceuticals · doi:10.3390/ph14111195 · Cited by 10 · cited 2×
“In addition, Glucosidase II is involved in human polycystic disease [8–10] and finally in the demyelinating ones of the central nervous system (CNS), according to the latest evidence [11].”
BackgroundSelf-citationManagement of psoriasis vulgaris and multiple sclerosis with fumaric acid
Gkalpakiotis, S., Arenberger, P., Gkalpakioti, P., Meluzinova, E., Chandran, D., & Arenbergerova, M. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.10.031 · Cited by 8 · cited 1×
“In addition, this finding is consistent with the alleviation of psoriasis vulgaris, also biologically characterized by UPR [455,456].”
ResultSchultze, B., Groβ, H.-J., Klenk, H., et al. (1990) · Advances in experimental medicine and biology · doi:10.1007/978-1-4684-5823-7_17 · Cited by 5 · cited 1×
“Viral glycan-binding proteins (hemagglutinins) such as 9-O-acetyl ester on the sialic acid side chain of certain coronaviruses and influenza C and D viruses are critical for binding host cells [56,95,96].”
BackgroundDe Masi, R., Orlando, S., & De Donno, A. (2021) · Pharmaceuticals · doi:10.3390/ph14020081 · Cited by 5 · cited 1×
“HCs and RRMS has been attributed to the well-known phenomenon of immunosenescence already described in MS [449,450].”
BackgroundSelf-citationThakkar, S. G., Heeger, P. S., Wacker, B., Roddy, M., Waxenecker, G., Himmler, G., Loibner, H., Elson, P. J., & Bukowski, R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.2586 · Cited by 3 · cited 1×
“Currently, some experimental vaccine therapeutics are approved, including GM2 KLH/QS-21 and MGV (GM2/GD2 KLH QS21) for malignant melanomas [257]; Theratope (sialyl-Tn Ag) for breast cancer [258]; IGN 301 (anti-idiotypic antibody) for LeY antigen associated with small cell lung cancer [259].”
BackgroundGlucosidase, Alpha Neutral AB; Glucosidase II Subunit Beta (GANAB, PRKCSH, α-Glucosidase II)
Nairn, A. V., & Moremen, K. W. (2014) · Springer eBooks · doi:10.1007/978-4-431-54240-7_140 · Cited by 2
Mondal, D. S. (2019) · doi:10.13140/rg.2.2.15056.25606 · Cited by 1
Research works printed but not linked: 8
- Varki A. Schauer R. Sialic Acids Essentials of Glycobiology 2nd ed. Varki A. Cummings R.D. Esko J.D. Freeze H.H. Stanley P. Bertozzi C.R. Hart G.W. Etzler M.E. Cold Spring Harbor Laboratory Press Cold Spring Harbor, NY, USA 2009 Chapter 14 Available online: https://www.ncbi.nlm.nih.gov/books/NBK1920/ (accessed on 28 February 2022)
- Taylor M.E. Drickamer K. Introduction to Glycobiology 2nd ed. Oxford University Press Oxford, UK 2006
- Varki A. Cummings R. Esko J. Freeze H.H. Stanley P. Bertozzi C.R. Hart G.W. Etzler M.E. Essentials of Glycobiology Cold Spring Harbor Laboratory Press Cold Spring Harbor, NY, USA 1999 Chapter 16 Available online: https://www.ncbi.nlm.nih.gov/books/NBK20705/ (accessed on 28 February 2022) 20301239
- Stanley P. Schachter H. Taniguchi N. N-Glycans Essentials of Glycobiology Varki A. Cummings R.D. Esko J.D. Freeze H.H. Stanley P. Bertozzi C.R. Hart G.W. Etzler M.E. Cold Spring Harbor Laboratory Press Cold Spring Harbor, NY, USA 2009 101 114
- Voet D. Voet J.G. Pratt C.W. Fundamentals of Biochemistry John Wiley & Sons, Inc. Hoboken, NJ, USA 1999
- Brockhausen I. Schachter H. Stanley P. O-GalNAc Glycans Essentials of Glycobiology 2nd ed. Varki A. Cummings R.D. Esko J.D. Freeze H.H. Stanley P. Bertozzi C.R. Hart G.W. Etzler M.E. Cold Spring Harbor Laboratory Press Cold Spring Harbor, NY, USA 2009 Chapter 9 20301232
- Zachara N. Akimoto Y. Hart G.W. The O-GlcNAc Modification Essentials of Glycobiology 3rd ed. Varki A. Cummings R.D. Esko J.D. Freeze H.H. Stanley P. Bertozzi C.R. Hart G.W. Etzler M.E. Cold Spring Harbor Laboratory Press Cold Spring Harbor, NY, USA 2017 Chapter 19 Available online: https://www.ncbi.nlm.nih.gov/books/NBK453063/ (accessed on 28 February 2022) 10.1101/glycobiology.3e.01 · doi:10.1101/glycobiology.3e.01
- Janeway C.A. Jr. Travers P. Walport M. Walport M. Shlomchik M.J. Antigen receptor structure and signaling pathways Immunobiology: The Immune System in Health and Disease 5th ed. Garland Science New York, NY, USA 2001 Available online: https://www.ncbi.nlm.nih.gov/books/NBK27130/ (accessed on 28 February 2022)
Cited by
Multi-scale signaling and tumor evolution in high-grade gliomas
Liu, J., Cao, S., Imbach, K. J., Gritsenko, M. A., Lih, T. M., Kyle, J. E., Yaron-Barir, T. M., Binder, Z. A., Li, Y., Strunilin, I., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.06.004 · Cited by 81
Ramaprabha, K., Kumar, S. V., Saravanan, P., Rajeshkannan, R., Rajasimman, M., Kamyab, H., & Vasseghian, Y. (2023) · Environmental Research · doi:10.1016/j.envres.2023.117521 · Cited by 91
Xue, X., Wu, X., Liu, L., Liu, L., & Zhu, F. (2023) · Viruses · doi:10.3390/v15061298 · Cited by 15
Withana, M., & Castorina, A. (2023) · Cells · doi:10.3390/cells12222633 · Cited by 12
“Post-mortem analyses of human CNS tissues have demonstrated the presence of activated IRE1 α and UPR in patients with Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS) [47].”
BackgroundSoloveva, N. A., Novikova, S. E., Farafonova, T. E., Tikhonova, O. V., & Zgoda, V. G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031016 · Cited by 10
Metadata
- Authors
- De Masi, R., & Orlando, S.
- Affiliations
- Complex Operative Unit of Neurology, “F. Ferrari” Hospital, Casarano, 73042 Lecce, Italy
- Laboratory of Neuroproteomics, Multiple Sclerosis Centre, “F. Ferrari” Hospital, Casarano, 73042 Lecce, Italy
- Corresponding author
- Orlando, Stefania
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-07-01
- Volume
- 23
- Issue
- 13
- Pages
- 7373
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC9266668
- OpenAlex
- W4283802200
- Cited by
- 20
- References
- 464
- Citations by year
- 2026: 7 · 2025: 5 · 2024: 3 · 2023: 5
- FWCI
- 0.34
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Endoplasmic Reticulum Stress and Disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
- Keywords
- GANAB, N-glycans, N-acetyl-beta-D-glucosaminidase, polycystic kidney disease, polycystic liver disease, multiple sclerosis, unfolded protein response, polycystin-1, polycystin-2, protein folding, glycosylation, ATF6, PERK, IRE1, BiP, systemic lupus erythematosus, cyst formation
- MeSH terms
- Glucose, Humans, Male, Multiple Sclerosis, Polysaccharides, TRPP Cation Channels, Unfolded Protein Response
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.